Abstract

One of the primary objectives of the AIDS Program is to support research activities which will provide information that can be used to improve the therapy of AIDS. The retrovirus HTLV-III/LAV has been identified as an essential factor in the etiology of the acquired immunodeficiency syndrome (AIDS). The findings of HTLV-III/LAV prompts research to develop and evaluate specific therapy against retroviruses and their maintenance enzyme systems. Nonhuman primates have been infected with HTLV-III/LAV although none of these animals have developed the cancers or opportunistic infections characteristic of AIDS. Therefore, no suitable endpoints exist to evaluate therapies in the infected primates. However, several naturally occurring retroviral diseases exist. The retroviruses that cause these diseases have many of the same enzyme systems as HTLV-III/LAV. Presumably understanding the activity of antivirals in animals will help plan clinical trials in humans infected with HTLV-III/LAV.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research and Development Contracts (N01)
Project #
N01AI062525-000
Application #
2296519
Study Section
Project Start
1985-12-16
Project End
Budget Start
1985-12-16
Budget End
1986-12-15
Support Year
Fiscal Year
1986
Total Cost
Indirect Cost

  Institution

Name
Ohio State University
Department
Veterinary Sciences
Type
Schools of Veterinary Medicine
DUNS #
098987217
City
Columbus
State
OH
Country
United States
Zip Code
43210

  Publications

Tochikura, T S; Tanabe-Tochikura, A; Hayes, K A et al. (1993) Fusion activity dissociated from replication ability in feline immunodeficiency virus (FIV) in human cells. J Acquir Immune Defic Syndr 6:1301-10
Tanabe-Tochikura, A; Tochikura, T S; Blakeslee Jr, J R et al. (1992) Anti-human immunodeficiency virus (HIV) agents are also potent and selective inhibitors of feline immunodeficiency virus (FIV)-induced cytopathic effect: development of a new method for screening of anti-FIV substances in vitro. Antiviral Res 19:161-72
Mathes, L E; Polas, P J; Hayes, K A et al. (1992) Pre- and postexposure chemoprophylaxis: evidence that 3'-azido-3'-dideoxythymidine inhibits feline leukemia virus disease by a drug-induced vaccine response. Antimicrob Agents Chemother 36:2715-21
Hayes, K A; Rojko, J L; Mathes, L E (1992) Incidence of localized feline leukemia virus infection in cats. Am J Vet Res 53:604-7
Swenson, C L; Weisbrode, S E; Nagode, L A et al. (1991) Age-related differences in phosphonoformate-induced bone toxicity in cats. Calcif Tissue Int 48:353-61
Mathes, L E; Hayes, K A; Swenson, C L et al. (1991) Evaluation of antiviral activity and toxicity of dextran sulfate in feline leukemia virus-infected cats. Antimicrob Agents Chemother 35:2147-50
Swenson, C L; Polas, P J; Cheney, C M et al. (1991) Prophylactic and therapeutic effects of phosphonoformate against feline leukemia virus in vitro. Am J Vet Res 52:2010-5
Swenson, C L; Sams, R A; Polas, P J et al. (1990) Age-related differences in pharmacokinetics of phosphonoformate in cats. Antimicrob Agents Chemother 34:871-4
Tochikura, T S; Hayes, K A; Cheney, C M et al. (1990) In vitro replication and cytopathogenicity of the feline immunodeficiency virus for feline T4 thymic lymphoma 3201 cells. Virology 179:492-7
Polas, P J; Swenson, C L; Sams, R et al. (1990) In vitro and in vivo evidence that the antiviral activity of 2',3'-dideoxycytidine is target cell dependent in a feline retrovirus animal model. Antimicrob Agents Chemother 34:1414-21

Showing the most recent 10 out of 13 publications